| Value |
Description |
German Interpretation |
Comment |
Chapter |
| 54 |
adenovirus, type 4 |
|
adenovirus vaccine, type 4, live, oral |
2.C.2.135 |
| 55 |
adenovirus, type 7 |
|
adenovirus vaccine, type 7, live, oral |
2.C.2.135 |
| 82 |
adenovirus, NOS1 |
|
adenovirus vaccine, NOS |
2.C.2.135 |
| 24 |
anthrax |
|
anthrax vaccine |
2.C.2.135 |
| 19 |
BCG |
|
Bacillus Calmette-Guerin vaccine |
2.C.2.135 |
| 27 |
botulinum antitoxin |
|
botulinum antitoxin |
2.C.2.135 |
| 26 |
cholera |
|
cholera vaccine |
2.C.2.135 |
| 29 |
CMVIG |
|
cytomegalovirus immune globulin, intravenous |
2.C.2.135 |
| 56 |
dengue fever |
|
dengue fever vaccine |
2.C.2.135 |
| 12 |
diphtheria antitoxin |
|
diphtheria antitoxin |
2.C.2.135 |
| 28 |
DT (pediatric) |
|
diphtheria and tetanus toxoids, adsorbed for pediatric use |
2.C.2.135 |
| 20 |
DTaP |
|
diphtheria, tetanus toxoids and acellular pertussis vaccine |
2.C.2.135 |
| 106 |
DTaP, 5 pertussis antigens6 |
|
diphtheria, tetanus toxoids and acellular pertussis vaccine, 5 pertussis antigens |
2.C.2.135 |
| 107 |
DTaP, NOS |
|
diphtheria, tetanus toxoids and acellular pertussis vaccine, NOS |
2.C.2.135 |
| 110 |
DTaP-Hep B-IPV |
|
DTaP-hepatitis B and poliovirus vaccine |
2.C.2.135 |
| 50 |
DTaP-Hib |
|
DTaP-Haemophilus influenzae type b conjugate vaccine |
2.C.2.135 |
| 120 |
DTaP-Hib-IPV |
|
diphtheria, tetanus toxoids and acellular pertussis vaccine, Haemophilus influenzae type b conjugate, and poliovirus vaccine, inactivated (DTaP-Hib-IPV) |
2.C.2.135 |
| 01 |
DTP |
|
diphtheria, tetanus toxoids and pertussis vaccine |
2.C.2.135 |
| 22 |
DTP-Hib |
|
DTP-Haemophilus influenzae type b conjugate vaccine |
2.C.2.135 |
| 102 |
DTP-Hib-Hep B |
|
DTP- Haemophilus influenzae type b conjugate and hepatitis b vaccine |
2.C.2.135 |
| 57 |
hantavirus |
|
hantavirus vaccine |
2.C.2.135 |
| 52 |
Hep A, adult |
|
hepatitis A vaccine, adult dosage |
2.C.2.135 |
| 83 |
Hep A, ped/adol, 2 dose |
|
hepatitis A vaccine, pediatric/adolescent dosage, 2 dose schedule |
2.C.2.135 |
| 84 |
Hep A, ped/adol, 3 dose |
|
hepatitis A vaccine, pediatric/adolescent dosage, 3 dose schedule |
2.C.2.135 |
| 31 |
Hep A, pediatric, NOS |
|
hepatitis A vaccine, pediatric dosage, NOS |
2.C.2.135 |
| 85 |
Hep A, NOS |
|
hepatitis A vaccine, NOS |
2.C.2.135 |
| 104 |
Hep A-Hep B |
|
hepatitis A and hepatitis B vaccine |
2.C.2.135 |
| 30 |
HBIG |
|
hepatitis B immune globulin |
2.C.2.135 |
| 08 |
Hep B, adolescent or pediatric |
|
hepatitis B vaccine, pediatric or pediatric/adolescent dosage |
2.C.2.135 |
| 42 |
Hep B, adolescent/high risk infant2 |
|
hepatitis B vaccine, adolescent/high risk infant dosage |
2.C.2.135 |
| 43 |
Hep B, adult4 |
|
hepatitis B vaccine, adult dosage |
2.C.2.135 |
| 44 |
Hep B, dialysis |
|
hepatitis B vaccine, dialysis patient dosage |
2.C.2.135 |
| 45 |
Hep B, NOS |
|
hepatitis B vaccine, NOS |
2.C.2.135 |
| 58 |
Hep C |
|
hepatitis C vaccine |
2.C.2.135 |
| 59 |
Hep E |
|
hepatitis E vaccine |
2.C.2.135 |
| 60 |
herpes simplex 2 |
|
herpes simplex virus, type 2 vaccine |
2.C.2.135 |
| 46 |
Hib (PRP-D) |
|
Haemophilus influenzae type b vaccine, PRP-D conjugate |
2.C.2.135 |
| 47 |
Hib (HbOC) |
|
Haemophilus influenzae type b vaccine, HbOC conjugate |
2.C.2.135 |
| 48 |
Hib (PRP-T) |
|
Haemophilus influenzae type b vaccine, PRP-T conjugate |
2.C.2.135 |
| 49 |
Hib (PRP-OMP) |
|
Haemophilus influenzae type b vaccine, PRP-OMP conjugate |
2.C.2.135 |
| 17 |
Hib, NOS |
|
Haemophilus influenzae type b vaccine, conjugate NOS |
2.C.2.135 |
| 51 |
Hib-Hep B |
|
Haemophilus influenzae type b conjugate and Hepatitis B vaccine |
2.C.2.135 |
| 61 |
HIV |
|
human immunodeficiency virus vaccine |
2.C.2.135 |
| 118 |
HPV, bivalent |
|
human papilloma virus vaccine, bivalent |
2.C.2.135 |
| 62 |
HPV, quadrivalent |
|
human papilloma virus vaccine, quadrivalent |
2.C.2.135 |
| 86 |
IG |
|
immune globulin, intramuscular |
2.C.2.135 |
| 87 |
IGIV |
|
immune globulin, intravenous |
2.C.2.135 |
| 14 |
IG, NOS |
|
immune globulin, NOS |
2.C.2.135 |
| 111 |
influenza, live, intranasal |
|
influenza virus vaccine, live, attenuated, for intranasal use |
2.C.2.135 |
| 15 |
influenza, split (incl. purified surface antigen) |
|
influenza virus vaccine, split virus (incl. purified surface antigen) |
2.C.2.135 |
| 16 |
influenza, whole |
|
influenza virus vaccine, whole virus |
2.C.2.135 |
| 88 |
influenza, NOS |
|
influenza virus vaccine, NOS |
2.C.2.135 |
| 10 |
IPV |
|
poliovirus vaccine, inactivated |
2.C.2.135 |
| 02 |
OPV |
|
poliovirus vaccine, live, oral |
2.C.2.135 |
| 89 |
polio, NOS |
|
poliovirus vaccine, NOS |
2.C.2.135 |
| 39 |
Japanese encephalitis |
|
Japanese encephalitis vaccine |
2.C.2.135 |
| 63 |
Junin virus |
|
Junin virus vaccine |
2.C.2.135 |
| 64 |
leishmaniasis |
|
leishmaniasis vaccine |
2.C.2.135 |
| 65 |
leprosy |
|
leprosy vaccine |
2.C.2.135 |
| 66 |
Lyme disease |
|
Lyme disease vaccine |
2.C.2.135 |
| 03 |
MMR |
|
measles, mumps and rubella virus vaccine |
2.C.2.135 |
| 04 |
M/R |
|
measles and rubella virus vaccine |
2.C.2.135 |
| 94 |
MMRV |
|
measles, mumps, rubella, and varicella virus vaccine |
2.C.2.135 |
| 67 |
malaria |
|
malaria vaccine |
2.C.2.135 |
| 05 |
measles |
|
measles virus vaccine |
2.C.2.135 |
| 68 |
melanoma |
|
melanoma vaccine |
2.C.2.135 |
| 32 |
meningococcal |
|
meningococcal polysaccharide vaccine (MPSV4) |
2.C.2.135 |
| 103 |
meningococcal C conjugate |
|
meningococcal C conjugate vaccine |
2.C.2.135 |
| 114 |
meningococcal A,C,Y,W-135 diphtheria conjugate |
|
meningococcal polysaccharide (groups A, C, Y and W-135) diphtheria toxoid conjugate vaccine (MCV4) |
2.C.2.135 |
| 108 |
meningococcal, NOS |
|
meningococcal vaccine, NOS |
2.C.2.135 |
| 07 |
mumps |
|
mumps virus vaccine |
2.C.2.135 |
| 69 |
parainfluenza-3 |
|
parainfluenza-3 virus vaccine |
2.C.2.135 |
| 11 |
pertussis |
|
pertussis vaccine |
2.C.2.135 |
| 23 |
plague |
|
plague vaccine |
2.C.2.135 |
| 33 |
pneumococcal |
|
pneumococcal polysaccharide vaccine |
2.C.2.135 |
| 100 |
pneumococcal conjugate |
|
pneumococcal conjugate vaccine, polyvalent |
2.C.2.135 |
| 109 |
pneumococcal, NOS |
|
pneumococcal vaccine, NOS |
2.C.2.135 |
| 70 |
Q fever |
|
Q fever vaccine |
2.C.2.135 |
| 18 |
rabies, intramuscular injection |
|
rabies vaccine, for intramuscular injection |
2.C.2.135 |
| 40 |
rabies, intradermal injection |
|
rabies vaccine, for intradermal injection |
2.C.2.135 |
| 90 |
rabies, NOS |
|
rabies vaccine, NOS |
2.C.2.135 |
| 72 |
rheumatic fever |
|
rheumatic fever vaccine |
2.C.2.135 |
| 73 |
Rift Valley fever |
|
Rift Valley fever vaccine |
2.C.2.135 |
| 34 |
RIG |
|
rabies immune globulin |
2.C.2.135 |
| 119 |
rotavirus, monovalent |
|
rotavirus, live, monovalent vaccine |
2.C.2.135 |
| 122 |
rotavirus, NOS1 |
|
rotavirus vaccine, NOS |
2.C.2.135 |
| 116 |
rotavirus, pentavalent |
|
rotavirus, live, pentavalent vaccine |
2.C.2.135 |
| 74 |
rotavirus, tetravalent |
|
rotavirus, live, tetravalent vaccine |
2.C.2.135 |
| 71 |
RSV-IGIV |
|
respiratory syncytial virus immune globulin, intravenous |
2.C.2.135 |
| 93 |
RSV-MAb |
|
respiratory syncytial virus monoclonal antibody (palivizumab), intramuscular |
2.C.2.135 |
| 06 |
rubella |
|
rubella virus vaccine |
2.C.2.135 |
| 38 |
rubella/mumps |
|
rubella and mumps virus vaccine |
2.C.2.135 |
| 76 |
Staphylococcus bacterio lysate |
|
Staphylococcus bacteriophage lysate |
2.C.2.135 |
| 113 |
Td (adult) |
|
tetanus and diphtheria toxoids, adsorbed, preservative free, for adult use |
2.C.2.135 |
| 09 |
Td (adult) |
|
tetanus and diphtheria toxoids, adsorbed for adult use |
2.C.2.135 |
| 115 |
Tdap |
|
tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine, adsorbed |
2.C.2.135 |
| 35 |
tetanus toxoid |
|
tetanus toxoid, adsorbed |
2.C.2.135 |
| 112 |
tetanus toxoid, NOS |
|
tetanus toxoid, NOS |
2.C.2.135 |
| 77 |
tick-borne encephalitis |
|
tick-borne encephalitis vaccine |
2.C.2.135 |
| 13 |
TIG |
|
tetanus immune globulin |
2.C.2.135 |
| 95 |
TST-OT tine test |
|
tuberculin skin test; old tuberculin, multipuncture device |
2.C.2.135 |
| 96 |
TST-PPD intradermal |
|
tuberculin skin test; purified protein derivative solution, intradermal |
2.C.2.135 |
| 97 |
TST-PPD tine test |
|
tuberculin skin test; purified protein derivative, multipuncture device |
2.C.2.135 |
| 98 |
TST, NOS |
|
tuberculin skin test; NOS |
2.C.2.135 |
| 78 |
tularemia vaccine |
|
tularemia vaccine |
2.C.2.135 |
| 91 |
typhoid, NOS |
|
typhoid vaccine, NOS |
2.C.2.135 |
| 25 |
typhoid, oral |
|
typhoid vaccine, live, oral |
2.C.2.135 |
| 41 |
typhoid, parenteral |
|
typhoid vaccine, parenteral, other than acetone-killed, dried |
2.C.2.135 |
| 53 |
typhoid, parenteral, AKD (U.S. military) |
|
typhoid vaccine, parenteral, acetone-killed, dried (U.S. military) |
2.C.2.135 |
| 101 |
typhoid, ViCPs |
|
typhoid Vi capsular polysaccharide vaccine |
2.C.2.135 |
| 75 |
vaccinia (smallpox) |
|
vaccinia (smallpox) vaccine |
2.C.2.135 |
| 105 |
vaccinia (smallpox) diluted |
|
vaccinia (smallpox) vaccine, diluted |
2.C.2.135 |
| 79 |
vaccinia immune globulin |
|
vaccinia immune globulin |
2.C.2.135 |
| 21 |
varicella |
|
varicella virus vaccine |
2.C.2.135 |
| 81 |
VEE, inactivated |
|
Venezuelan equine encephalitis, inactivated |
2.C.2.135 |
| 80 |
VEE, live |
|
Venezuelan equine encephalitis, live, attenuated |
2.C.2.135 |
| 92 |
VEE, NOS |
|
Venezuelan equine encephalitis vaccine, NOS |
2.C.2.135 |
| 36 |
VZIG |
|
varicella zoster immune globulin |
2.C.2.135 |
| 117 |
VZIG (IND) |
|
varicella zoster immune globulin (Investigational New Drug) |
2.C.2.135 |
| 37 |
yellow fever |
|
yellow fever vaccine |
2.C.2.135 |
| 121 |
zoster |
|
zoster vaccine, live |
2.C.2.135 |
| 998 |
no vaccine administered5 |
|
no vaccine administered |
2.C.2.135 |
| 999 |
unknown |
|
unknown vaccine or immune globulin |
2.C.2.135 |
| 99 |
RESERVED - do not use3 |
|
RESERVED - do not use |
2.C.2.135 |